{"name":"South Eastern European Research Oncology Group","slug":"south-eastern-european-research-oncology-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Capecitabine and Bevacizumab","genericName":"Capecitabine and Bevacizumab","slug":"capecitabine-and-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_2"}]}],"pipeline":[{"name":"Capecitabine and Bevacizumab","genericName":"Capecitabine and Bevacizumab","slug":"capecitabine-and-bevacizumab","phase":"phase_2","mechanism":"Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.","indications":["Metastatic colorectal cancer","Metastatic breast cancer","Gastric cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSUt6TjhqalJoV0RyTGFjdVoyaUdFQ3VFbHlVNXBpQ2lPMXdmU2pXbGxSTWtmY0otM0dTZktkS3pXVXk2Y2RYTnAtOUJJTDlzRkFwOXlkaDNMTS1lYm4wMXNZbGpuYWhTUFZHUlF2clJHU2tLaVQ3WXFDQ1E5WFJBR2hiY3dPNUFQbURaZjNJOGlUU3lSTGZHUkxJOGtBaUJnTW9SZ3JtMXN2bUdMY3psLU15dzBMX2ZR?oc=5","date":"2026-01-07","type":"pipeline","source":"McKinsey & Company","summary":"The emerging epicenter: Asia’s role in biopharma’s future - McKinsey & Company","headline":"The emerging epicenter: Asia’s role in biopharma’s future - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUExpb2dZRERKSEtkTERtWFQ0VFU3MmFSRjlNdlhpQVVNWk1OTjF6NkU3UFJjMk53NGNSc0ZfeHliaXR6dFZFZzdRaUhfTGVlNVNsclhuYXZvVUFqdWFLMElKbGlJOUVKYVIwTUdzNTEzYnQ5ZGFkX0FadW9vakIxb1l2b0tzaklkb0d6WlFR?oc=5","date":"2025-10-08","type":"pipeline","source":"Frontiers","summary":"A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America - Frontiers","headline":"A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNZm1xUWpPcE93ZWJuNGZEakNyOVN6YS0yLVRwNTRhUWhBY0ktNWVraUEtMkJyS0pDQkt5cDQ4U2loUFh6dG1VNjdmVlpjOENIZ1Q3NTdfZUFXd1hkeFdzc1NUSEZibXJsRU5aRE8taUlxd0g3X1VxWllYS1NsTmlGUlJTa3JBMk9HVHN0Q29HeGJVTU9rd1JQOUZCVGxUTHVEV3ZoUGE1Qi1HZW5xTlF2ekJKVHNHYkg0ZS1iNG9PNjdPMjlBZUN6WUd4R0wyaGdqSmVYTWRGN0VBOFZNN2pRSzdhYzFtbmZZbkNjVXFMZm42VFE?oc=5","date":"2025-10-07","type":"pipeline","source":"prnewswire.com","summary":"Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - prnewswire.com","headline":"Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE8xWk1xaDhaaTBzalJQMFBmbDhyUlFuSjFObXFHemc2andOZ253YmdlMjNHY0hqajBNMlZGdnhMSGJaY0hYOExHcDJ6UWpmWVU3c2d5QWdLSlVsSHpUX29Ua0dHbV9iR3hDWHN1cXJNY1pVTVFh?oc=5","date":"2025-10-01","type":"trial","source":"Straits Research","summary":"Oncology Clinical Trials Market Size, Share, Players & Trends by 2034 - Straits Research","headline":"Oncology Clinical Trials Market Size, Share, Players & Trends by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQRFE1MURTRUhqZTFqa0Jzb3lDaEQ1VDNMaFZmaFJQTlJPeE9ISVVBQTNCMG5HU0NBeTJyRzl4ZzJqVGp6d21YTG40cVNvMENOT0IyWjRPdTg4VThkSHdPYk9hVGpaWWhUWmxYX3lkVjY4bEFVeHBtXzdLU3dtZm1pRUxOcDFla240WVJjcEFQemVTZ1lleDJGZUhzLTV4RjZiNjc1WnN3?oc=5","date":"2025-02-08","type":"pipeline","source":"Bain & Company","summary":"Healing the World: A Roadmap for Making India a Global Pharma Exports Hub - Bain & Company","headline":"Healing the World: A Roadmap for Making India a Global Pharma Exports Hub - Bain & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5nekxtUHFNZGRvR0l2SHN5VDcwaVlBd193RUtBN3M0MWNndnAxRmpheVVOYVBwTjM3d0ZCRTJrOVYyZ1FhbEVjMURFdlpWX1RVR2h5VTE5V2YzWXJ6UU9Iam5FMV91Mi1lbEphMVpqSGtBM3RGQkp2UUZR?oc=5","date":"2024-12-04","type":"pipeline","source":"Oncodaily","summary":"100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024 - Oncodaily","headline":"100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBONEttRGE3V2RoajRCMDFVU2ZadmM4TGh2NkxDRnhEMW1Ldkd1ckdjTVk2MnRZZzhmT1QwVjRuTVlkS0Fra1A3UF9oNkRTN0FWeU9QRlpqLTVzcV9ZQ0JlbzRlWnZJRUtVU2RFeVppaTdLYzg?oc=5","date":"2024-09-27","type":"pipeline","source":"Market.us Media","summary":"Top 10 Breast Cancer Treatment Providers | Provides Best Solutions - Market.us Media","headline":"Top 10 Breast Cancer Treatment Providers | Provides Best Solutions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORDEteHdPSW9xYlJDeGdrNmUwWmVWT0dhTkk3UVEwSXNOaWhDM0V5Z2doZmx1M2pSRDdsUFFqd1ZYRkpBY0MzaVZsQ1pGV1FwQTFBa0N6U3VmTVN2V005a3AyaVRqZG5pV3FQQ1hWM2hXbmRqZ180VENVVXUtVkpxNWlPV1ZCUDY3bnI0?oc=5","date":"2024-04-04","type":"pipeline","source":"The Lancet","summary":"The Lancet Commission on prostate cancer: planning for the surge in cases - The Lancet","headline":"The Lancet Commission on prostate cancer: planning for the surge in cases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE85NjVkcWhhMUhMWVVxMG1uLTE1dldPajlYWEdySTZKSTE1azIwdERMTXhHVHVzdEpBdVVGeHY4OWV5a0I5RWZqc0Y2X3NuX181MjY4VUtNdngwYnFXeGcw?oc=5","date":"2022-11-15","type":"pipeline","source":"Nature","summary":"Barriers in access to oncology drugs — a global crisis - Nature","headline":"Barriers in access to oncology drugs — a global crisis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5hNy1UaThiSGpneG40aGxrY0tjTkQtNGthdHRpbE5oNFRnbHJsWG9RQW45dTZMV2pKM012eUlJbXhLQ29FRV8tWlJybXhjaU5RVEprTklZSFBYY1N1Q05WdGFoUV8wdGUwMEZSbWdzR0tTcU5PWkJvSQ?oc=5","date":"2019-05-14","type":"pipeline","source":"CancerNetwork","summary":"State of Cancer Research Around the Globe - CancerNetwork","headline":"State of Cancer Research Around the Globe","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}